Top 5 Performing Companies To Invest In Right Now

Northrop Grumman (NYSE: NOC  ) came away with more contract wins than anyone else Tuesday on the Pentagon's supplier list, scoring two contracts worth nearly $53 million, combined.

The larger of the two contracts, worth $40.5 million, tasks Northrop's Information Systems division with performing research and development, enhancement, integration, deployment and sustainment work related to the Secure Access Baseline for the EnterpRise (SABER) initiative for the Air Force Intelligence, Surveillance and Reconnaissance Agency, the Department of Homeland Security, the Defense Intelligence Agency, and other intelligence community and Department of Defense customers. Northrop has an April 9, 2018, completion date for this work.

The company also won a $12.4 million contract�to extend by four months its work on the Counter Rocket Artillery Mortar (C-RAM�) Command and Control System. C-RAM is a system that integrates the military's existing field artillery and air defense sensors with a commercial off-the-shelf warning system and a Navy-designed interceptor rocket to shoot down incoming indirect fire rounds -- mortars, artillery shells, and the like.

Top 5 Performing Companies To Invest In Right Now: Tox Free Solutions Ltd(TOX.AX)

Tox Free Solutions Limited, together with its subsidiaries, provides waste management and industrial services in Australia. The company offers chemical and hazardous waste treatment services for various materials, such as hydrocarbon contaminated soils and sludges, flammable wastes, pesticide wastes, oils and emulsions, coolants and glycols, surfactants and cleaning products, acids and alkalis, laboratory wastes, oxidizers, schedule X compounds, heavy metal bearing wastes, and spent catalysts. It also provides contaminated site remediation services, including assessment and project management; and emergency response services comprising spills and chemical cleanup, controlled and dangerous goods licensed transport, spill response and personal protective equipment, and spills kit. In addition, the company offers industrial services, such as vacuum loading; high pressure jetting, drain cleaning, and de-contamination; concrete demolition; non destructive digging; girth gear cl eaning; tank, pit, and silo cleaning; tank degassing, decommissioning, disposal, and gas free testing and certification; decontamination and clearance of hazardous waste; cleaning and descaling of cold water storage tanks and cooling towers; interceptor and plate separator cleaning and servicing; onsite oil/water separation and sludge separation; and catalyst removal and change out services to mining, oil and gas, civil infrastructure, and manufacturing industries. Further, it provides liquid waste treatment services for a range of hazardous and non hazardous bulk liquid wastes; marine and tank cleaning services consisting of cleaning of tanks, vessels, bilges, and industrial machinery, as well as liquid waste collection and waste treatment; residential, commercial, and industrial solid waste management and recycling services; and household hazardous waste collection and management services. The company was founded in 2001 and is based in West Perth, Australia.

Top 5 Performing Companies To Invest In Right Now: Health Management Associates Inc.(HMA)

Health Management Associates, Inc., through its subsidiaries, engages in the operation of general acute care hospitals and other health care facilities in non-urban communities in the United States. Its hospitals provide services, including general surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic care, coronary care, and pediatric services. The company also offers outpatient services, such as one-day surgery, laboratory, x-ray, respiratory therapy, cardiology, and physical therapy. In addition, its hospitals provide specialty services in cardiology, neuro-surgery, oncology, radiation therapy, computer-assisted tomography scanning, magnetic resonance imaging, lithotripsy, and full-service obstetrics. As of December 31, 2011, the company operated 66 hospitals with a total of 10,330 licensed beds in non-urban communities in Alabama, Arkansas, Florida, Georgia, Kentucky, Mississippi, Missouri, North Carolina, Oklahoma, Pennsylvania, South Carolina, Tennessee, Texas, Washington, and West Virginia. Health Management Associates was founded in 1977 and is based in Naples, Florida.

5 Best Warren Buffett Stocks To Own For 2014: 7 Days Group Holdings Limited(SVN)

7 Days Group Holdings Limited, through its subsidiaries, operates a chain of limited service economy hotels under the brand name of 7 Days Inn in China. The company provides accommodations and services primarily to business and leisure travelers. As of December 31, 2010, it operated 568 hotels in operation, including 247 managed hotels, with 56,410 hotel rooms in 89 cities, as well as 197 hotels with 19,345 hotel rooms under conversion. The company was founded in 2004 and is based in Guangzhou, China.

Top 5 Performing Companies To Invest In Right Now: Telik Inc (TELK.PH)

Telik, Inc. (Telik), incorporated in 1988, is a clinical-stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The Company discovers its product candidates using the Company�� drug discovery technology, Target-Related Affinity Profiling (TRAP). TELINTRA, its principal drug product candidate in clinical development, is a small molecule glutathione analog inhibitor of the enzyme glutathione S-transferase P1-1 (GST P1-1). TELCYTA, its other product candidate, is a small molecule cancer drug product candidate designed to be activated in cancer cells.

Clinical Product Development

TELINTRA is the Company�� lead small molecule product candidate in clinical development for the treatment of blood disorders, including cancer. It has a mechanism of action and acts by inhibiting GST P1-1, an enzyme that is involved in the control of cellular growth and differentiation. Inhibition of GST P1-1 results in the activation of the signaling molecule Jun kinase, a regulator of the function of blood precursor cells. Preclinical tests show that TELINTRA is capable of causing the death or apoptosis of leukemic or malignant blood cells, while stimulating the growth and development of normal blood precursor cells. TELINTRA has been studied in Myelodysplastic Syndrome (MDS) using two formulations. A liposomal formulation was developed for intravenous administration of TELINTRA and was used in Phase I and Phase II studies in MDS patients. The results from the Phase II intravenous liposomal TELINTRA clinical trials demonstrated that TELINTRA treatment was associated with improvement in all three types of blood cell levels in patients with all types of MDS, including those in intermediate and high-risk groups. An oral dosage formulation (tablet) was subsequently developed and results from a Phase I study with TELINTRA tablets showed clinical activity and the formulation to be well tole rated. In June 2011, the Company initiated a Phase II clini! c! al trial to evaluate TELINTRA tablets. In October 2011, the Company initiated an additional Phase IIb clinical trial to evaluate TELINTRA tablets. '

The activity and safety profile of tablet formulation allowed the Company to complete a Phase II trial of TELINTRA tablets in MDS. The primary objective of the Phase II TELINTRA tablet study was to determine the efficacy of TELINTRA. A multivariate logistic regression analysis was conducted to identify MDS disease prognostic factors associated with erythroid improvement response rates, including prior MDS treatment, age, gender, the international prognostic scoring system (IPSS), risk, Eastern Cooperative Group performance status, years from MDS diagnosis, MDS World Health Organization subtypes, anemia only versus anemia plus other cytopenias, dose schedule and starting dose. Results from this study show that TELINTRA is the first GSTP1-1 enzyme inhibitor shown to cause clinically reductions in red blood cell transf usions, including transfusion independence in low to intermediate-1 risk MDS patients, as well as improvement in platelet count and white blood cell levels in certain patients. TELINTRA, administered orally twice daily, appeared to be convenient and flexible for chronic treatment administration.

TELCYTA is a small molecule drug product candidate that the Company is developed for the treatment of cancer. TELCYTA binds to GST. TELCYTA has been evaluated in multiple Phase II and Phase III clinical trials, including trials using TELCYTA as monotherapy and in combination regimens in ovarian, non-small cell lung, breast and colorectal cancer. Results from these clinical trials indicate that TELCYTA monotherapy was generally well-tolerated, with mostly mild to moderate side effects, particularly when compared to the side effects and toxicities of standard chemotherapeutic drugs. When TELCYTA was evaluated in combination with standard chemotherapeutic drugs, the tolera bility of the combinations was similar to that expected! of e! ac! h drug ! alone.

Clinical activity including objective tumor responses and/or disease stabilization was reported in the TELCYTA Phase II trials; however, TELCYTA did not meet its primary endpoints in the Phase III studies. Positive results from a Phase I-IIa multicenter, dose-ranging study of TELCYTA in combination with carboplatin and paclitaxel as first-line therapy for patients with non-small cell lung cancer, or NSCLC, were published in a peer reviewed publication. Clinical data demonstrated positive results of TELCYTA in combination with carboplatin and paclitaxel in the treatment of first-line lung cancer followed by TELCYTA maintenance therapy. As of December 31, 2011, the Company had an on-going investigator-led study at a single site of TELCYTA in patients with refractory or relapsed mantle cell lymphoma, diffuse B cell lymphoma, and multiple myeloma.

Preclinical Drug Product Development

The Company has a small molecule compound, TLK60 404, in preclinical development that inhibits both Aurora kinase and VEGFR kinase. Aurora kinase is a signaling enzyme whose function is required for cancer cell division, while VEGF plays a key role in tumor blood vessel formation, ensuring an adequate supply of nutrients to support tumor growth. These lead compounds prevented tumor growth in preclinical models of human colon cancer and human leukemia by inhibiting both Aurora kinase and VEGFR kinase. A development drug product candidate, TLK60404, has been selected.

The Company, using its TRAP technology has discovered TLK60357, a novel, potent small molecule inhibitor of cell division. TLK60357 inhibits the formation of microtubules that are necessary for cancer cell growth leading to persistent G2/M cancer cell cycle block and subsequent cell death. This compound demonstrates potent broad-spectrum anticancer activity against a number of human cancer cells. This compound also displays oral efficacy in multipl e, standard preclinical models of cancer. TLK6059! 6, a pote! nt! VGFR kin! ase inhibitor, blocks the formation of new blood vessels in tumors. Oral administration of TLK60596 to animal models of human colon cancer reduced tumor growth.

Top 5 Performing Companies To Invest In Right Now: AMCIL Ltd(AMH.AX)

Amcil Limited is a publicly owned investment manager. The firm primarily manages separate client focused equity portfolios for its clients. It invests in the public equity markets of Australia. The firm invests in growth and value stocks of large cap and small cap companies to create its portfolios. It invests in companies from media, technology, communications, and entertainment sectors. Amcil Limited was founded in 1996 and is based in Melbourne, Australia.